株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ベッカー型筋ジストロフィー:パイプライン製品の分析

Becker Muscular Dystrophy - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 321917
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
ベッカー型筋ジストロフィー:パイプライン製品の分析 Becker Muscular Dystrophy - Pipeline Review, H2 2016
出版日: 2016年08月24日 ページ情報: 英文 46 Pages
概要

ベッカー型筋ジストロフィーは、遺伝性の神経変性疾患の一種で、随意筋に症状が現れます。疼痛や走行、跳躍、つま先立ちなどの動作困難、呼吸困難、認識障害などが症状としてあげられます。

当レポートでは、ベッカー型筋ジストロフィーに対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

ベッカー型筋ジストロフィーの概要

治療薬の開発

  • パイプライン製品:概要

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Milo Biotechnology LLC
  • PTC Therapeutics, Inc.
  • ReveraGen BioPharma, Inc.
  • Sarepta Therapeutics, Inc.
  • Sphaera Pharma Pvt. Ltd

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • AAV1-FS-344
  • Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD
  • ARM-210
  • ataluren
  • epicatechin
  • Small Molecule for Becker Muscular Dystrophy
  • vamorolone

最新のパイプライン製品情報

開発休止中のプロジェクト

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8391IDB

Summary

Global Markets Direct's, 'Becker Muscular Dystrophy - Pipeline Review, H2 2016', provides an overview of the Becker Muscular Dystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy
  • The report reviews pipeline therapeutics for Becker Muscular Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Becker Muscular Dystrophy therapeutics and enlists all their major and minor projects
  • The report assesses Becker Muscular Dystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Becker Muscular Dystrophy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Becker Muscular Dystrophy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Becker Muscular Dystrophy Overview
  • Therapeutics Development
    • Pipeline Products for Becker Muscular Dystrophy - Overview
  • Becker Muscular Dystrophy - Therapeutics under Development by Companies
  • Becker Muscular Dystrophy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Becker Muscular Dystrophy - Products under Development by Companies
  • Becker Muscular Dystrophy - Companies Involved in Therapeutics Development
    • Milo Biotechnology LLC
    • PTC Therapeutics, Inc.
    • ReveraGen BioPharma, Inc.
    • Sarepta Therapeutics, Inc.
    • Sphaera Pharma Pvt. Ltd.
  • Becker Muscular Dystrophy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AAV1-Foliistatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARM-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ataluren - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epicatechin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Becker Muscular Dystrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vamorolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Becker Muscular Dystrophy - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Becker Muscular Dystrophy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Becker Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H2 2016
  • Becker Muscular Dystrophy - Pipeline by PTC Therapeutics, Inc., H2 2016
  • Becker Muscular Dystrophy - Pipeline by ReveraGen BioPharma, Inc., H2 2016
  • Becker Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H2 2016
  • Becker Muscular Dystrophy - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Becker Muscular Dystrophy - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Becker Muscular Dystrophy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top